Antimineralocorticoid Challenge

Encyclopedia of Stress

Volumn , Issue , 2007, Pages 223-226

  Kellner, M ^a   Wiedemann, K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882835303     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012373947-6.00415-3     Document Type: Chapter

References (16)

1. Arvat E., Maccagno B., Giordano R., et al. Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. Journal of Clinical Endocrinology and Metabolism 2001, 86:3176-3181.
2. Born J., Steinbach D., Dodt C., Fehm H.-L. Blocking of central nervous mineralocorticoid receptors counteracts inhibition of pituitary-adrenal activity in human sleep. Journal of Clinical Endocrinology and Metabolism 1997, 82:1106-1110.
3. Deuschle M., Weber B., Colla M., et al. Mineralocorticoid receptor also modulated basal activity of hypothalamus-pituitary-adrenocortical system in humans. Neuroendocrinology 1998, 68:355-360.
4. Gesing A., Bilang-Bleuel A., Droste S.K., et al. Psychological stress increases hippocampal mineralocorticoid receptor levels: involvement of corticotropin-releasing hormone. Journal of Neuroscience 2001, 21:4822-4829.
5. Grottoli S., Giordano R., Maccagno B., et al. The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. Journal of Clinical Endocrinology and Metabolism 2002, 87:4616-4620.
6. Heuser I., Deuschle M., Weber A., et al. The role of mineralocorticoid receptors in the circadian activity of the human hypothalamus-pituitary-adrenal system: effect of age. Neurobiology of Aging 2000, 21:585-589.
7. Heuser I., Deuschle M., Weber B., Stalla G.K., Holsboer F. Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology 2000, 25:513-518.
8. Jahn H., Schick M., Kiefer F., et al. Metyrapone as additive treatment in major depresssion: a double-blind and placebo-controlled trial. Archives of General Psychiatry 2004, 61:1235-1344.
9. Kellner M., Baker D.G., Yassouridis A., et al. Mineralocorticoid receptor function in patients with posttraumatic stress disorder. American Journal of Psychiatry 2002, 159:1938-1940.
10. Otte C., Jahn H., Yassouridis A., et al. The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. Life Sciences 2003, 73:1835-1845.
11. Reul J.M.H.N., Gesing A., Droste S., et al. The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. European Journal of Pharmacology 2000, 405:235-249.
12. Seckl J.R. 11β-hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid action?. Frontiers in Neuroendocrinology 1997, 18:49-99.
13. Weinberger M.H. Eplenerone: a new selective aldosterone receptor antagonist. Drugs Today 2004, 40:481-485.
14. Wellhoener P., Born J., Fehm L.H., Dodt C. Elevated resting and exercise-induced cortisol levels after mineralocorticoid receptor blockade with canrenoate in healthy humans. Journal of Clinical Endocrinology and Metabolism 2004, 89:5048-5052.
15. Young E.A., Lopez J.F., Murphy-Weinberg V., Watson S.J., Akil H. The role of mineralocorticoid receptors in HPA axis regulation in humans. Journal of Clinical Endocrinology and Metabolism 1998, 83:3339-3345.
16. Young E.A., Lopez J.F., Murphy-Weinberg V., Watson S.J., Akil H. Mineralocorticoid receptor function in major depression. Archives of General Psychiatry 2003, 60:24-28.